# E2F2

## Overview
E2F2 is a gene that encodes the E2F transcription factor 2, a member of the E2F family of transcription factors, which are pivotal in regulating the cell cycle and cellular proliferation. The E2F2 protein is characterized by a winged-helix DNA-binding domain, facilitating its role as a transcription factor by binding to specific DNA sequences and regulating the expression of genes essential for the G1 to S phase transition in the cell cycle (Li2021The). E2F2 functions primarily in the nucleus and is involved in various cellular processes, including cell cycle progression, apoptosis, and liver regeneration (Li2021The). Its activity is modulated through interactions with other proteins, such as the retinoblastoma protein (pRb) and DP proteins, which influence its ability to bind DNA and activate transcription (Li2021The). E2F2's regulatory functions are critical for maintaining normal cellular growth and preventing abnormal proliferation, with implications in diseases such as cancer and diabetes (Iglesias2004Diabetes; Sears1997Identification).

## Structure
The E2F2 protein is a member of the E2F family of transcription factors, characterized by a winged-helix DNA-binding domain (DBD) that is highly conserved and essential for its function in regulating cell cycle gene expression (Li2021The). This domain facilitates dimerization, allowing E2F2 to form functional transcription factors by heterodimerizing with DP proteins such as DP-1, DP-2, or DP-3, which is necessary for high-affinity DNA binding (Li2021The). E2F2 also contains multiple protein-protein interaction domains, including a helix-loop-helix binding domain that mediates heterodimerization with Sp1, leading to synergistic activation of transcription (Li2021The). Other domains include a cyclinA/cdk2 binding domain, a hydrophobic heptad repeat dimerization domain, and an Rb protein binding domain (Li2021The).

The activity of E2F2 is modulated by acetylation, which enhances its stability, DNA binding, and transactivation activity. This acetylation can be reversed by 'pocket proteins' such as the retinoblastoma protein (pRb) and Rb-related proteins p107 and p130, which are regulated by cyclin-dependent kinases (CDKs) (Li2021The). During cell cycle progression, pRb is phosphorylated by G1 cyclin-dependent kinase complexes, inhibiting its ability to bind E2F2, which is then released and becomes transcriptionally active (Li2021The).

## Function
E2F transcription factor 2 (E2F2) is a crucial regulator of the cell cycle, particularly involved in the transition from the G1 phase to the S phase. In healthy human cells, E2F2 promotes cell cycle progression by activating genes necessary for DNA replication, such as cyclin A and E, which are essential for the G1/S transition (Sears1997Identification; Li2021The). E2F2 is regulated by the retinoblastoma protein (pRb) pathway; unphosphorylated pRb binds to E2F2 to repress its activity. Upon phosphorylation by cyclin-dependent kinases (CDKs), E2F2 is released, allowing it to activate target genes that promote cell proliferation (Li2021The).

E2F2 also plays a role in apoptosis, where it can induce both p53-dependent and p53-independent pathways, balancing cell proliferation and differentiation (Li2021The). It is involved in liver regeneration, stimulating the entry of cells into the S phase and promoting cell cycle progression (Li2021The). E2F2's activity is primarily nuclear, where it binds to specific DNA sequences to regulate gene expression (Li2021The). Its function is tightly regulated by cell growth signals, ensuring proper cell cycle control and preventing abnormal cell growth (Sears1997Identification).

## Clinical Significance
Mutations and alterations in the E2F2 gene have been linked to several diseases and conditions. In Huntington's disease, the rs2742976 SNP in the E2F2 gene is associated with a delay in the age of onset, suggesting that E2F2 may modify disease progression. The T allele of this SNP is linked to a 3-year delay in onset, potentially due to its impact on E2F2 gene expression (ValcárcelOcete2015Exploring).

In hematopoiesis, E2F2 mutations lead to defects similar to megaloblastic anemia, characterized by impaired red blood cell maturation and decreased reticulocyte production. These defects are cell-autonomous and result from impaired S phase progression in hematopoietic progenitors (Li2003Defective).

E2F2 also plays a role in pancreatic function. E2F1/E2F2 double-mutant mice develop diabetes and exocrine pancreatic insufficiency, with symptoms such as hyperglycemia and reduced insulin production. This condition is attributed to increased DNA replication and apoptosis in pancreatic cells, leading to atrophy and dysfunction (Iglesias2004Diabetes).

In liver regeneration, E2F2 is crucial for hepatocyte proliferation. E2F2 knockout mice exhibit impaired liver regeneration and delayed cell-cycle entry, highlighting its role in regulating genes essential for liver regeneration (Delgado2011A; Huntington2016The).

## Interactions
E2F2, a member of the E2F family of transcription factors, engages in various interactions with proteins and nucleic acids that are crucial for its regulatory functions. E2F2 forms heterodimeric complexes with DP proteins (DP-1, DP-2, or DP-3), which are essential for its high-affinity DNA binding and transcriptional activity (Li2021The). It also interacts with the retinoblastoma protein (pRb) and other pocket proteins, which modulate its activity. When pRb is phosphorylated by cyclin-dependent kinases (CDKs), E2F2 is released to activate genes necessary for cell cycle progression (Li2021The).

E2F2 can also interact with transcription factors such as SP1, leading to synergistic activation of transcription (DeGregori2002The). In T lymphocytes, E2F2 cooperates with the transcription factor CREB to repress the promoters of genes like Mcm5 and Chk1, with CREB's DNA binding activity contributing to this repression (Laresgoiti2013E2F2).

In the context of breast cancer, E2F2 is part of a signaling axis involving ZMIZ1 and the estrogen receptor (ER), where ZMIZ1 enhances ER-dependent expression of E2F2. This interaction is significant for cell cycle regulation and proliferation in ER-positive breast cancer cells (Zhao2024ZMIZ1). These interactions highlight E2F2's role in regulating complex cellular processes through its dynamic interactions with various proteins and nucleic acids.


## References


[1. (Huntington2016The) Justin T. Huntington, Xing Tang, Lindsey N. Kent, Carl R. Schmidt, and Gustavo Leone. The spectrum of e2f in liver disease-mediated regulation in biology and cancer: e2f in liver disease. Journal of Cellular Physiology, 231(7):1438–1449, February 2016. URL: http://dx.doi.org/10.1002/jcp.25242, doi:10.1002/jcp.25242. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcp.25242)

[2. (Li2021The) Luwen Li, Shiguan Wang, Yihang Zhang, and Jihong Pan. The e2f transcription factor 2: what do we know? BioScience Trends, 15(2):83–92, April 2021. URL: http://dx.doi.org/10.5582/bst.2021.01072, doi:10.5582/bst.2021.01072. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.5582/bst.2021.01072)

[3. (Zhao2024ZMIZ1) Weiye Zhao, Susanna F Rose, Ryan Blake, Aňze Godicelj, Amy E Cullen, Jack Stenning, Lucy Beevors, Marcel Gehrung, Sanjeev Kumar, Kamal Kishore, Ashley Sawle, Matthew Eldridge, Federico M Giorgi, Katherine S Bridge, Florian Markowetz, and Andrew N Holding. Zmiz1 enhances erα-dependent expression of e2f2 in breast cancer. Journal of Molecular Endocrinology, April 2024. URL: http://dx.doi.org/10.1530/jme-23-0133, doi:10.1530/jme-23-0133. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1530/jme-23-0133)

[4. (Li2003Defective) Feng X. Li, Jing W. Zhu, Christopher J. Hogan, and James DeGregori. Defective gene expression, s phase progression, and maturation during hematopoiesis in e2f1/e2f2 mutant mice. Molecular and Cellular Biology, 23(10):3607–3622, May 2003. URL: http://dx.doi.org/10.1128/mcb.23.10.3607-3622.2003, doi:10.1128/mcb.23.10.3607-3622.2003. This article has 76 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.23.10.3607-3622.2003)

[5. (Laresgoiti2013E2F2) Usua Laresgoiti, Aintzane Apraiz, Miguel Olea, Jone Mitxelena, Nerea Osinalde, José A. Rodriguez, Asier Fullaondo, and Ana M. Zubiaga. E2f2 and creb cooperatively regulate transcriptional activity of cell cycle genes. Nucleic Acids Research, 41(22):10185–10198, September 2013. URL: http://dx.doi.org/10.1093/nar/gkt821, doi:10.1093/nar/gkt821. This article has 44 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/nar/gkt821)

[6. (ValcárcelOcete2015Exploring) Leire Valcárcel-Ocete, Gorka Alkorta-Aranburu, Mikel Iriondo, Asier Fullaondo, María García-Barcina, José Manuel Fernández-García, Elena Lezcano-García, José María Losada-Domingo, Javier Ruiz-Ojeda, Amaia Álvarez de Arcaya, José María Pérez-Ramos, Raymund A. C. Roos, Jørgen E. Nielsen, Carsten Saft, Ana M. Zubiaga, and Ana Aguirre. Exploring genetic factors involved in huntington disease age of onset: e2f2 as a new potential modifier gene. PLOS ONE, 10(7):e0131573, July 2015. URL: http://dx.doi.org/10.1371/journal.pone.0131573, doi:10.1371/journal.pone.0131573. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0131573)

[7. (Sears1997Identification) Rosalie Sears, Kiyoshi Ohtani, and Joseph R. Nevins. Identification of positively and negatively acting elements regulating expression of the e2f2 gene in response to cell growth signals. Molecular and Cellular Biology, 17(9):5227–5235, September 1997. URL: http://dx.doi.org/10.1128/mcb.17.9.5227, doi:10.1128/mcb.17.9.5227. This article has 163 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.17.9.5227)

[8. (DeGregori2002The) James DeGregori. The genetics of the e2f family of transcription factors: shared functions and unique roles. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1602(2):131–150, June 2002. URL: http://dx.doi.org/10.1016/s0304-419x(02)00051-3, doi:10.1016/s0304-419x(02)00051-3. This article has 49 citations.](https://doi.org/10.1016/s0304-419x(02)00051-3)

[9. (Delgado2011A) Igotz Delgado, Olatz Fresnedo, Ainhoa Iglesias, Yuri Rueda, Wing-Kin Syn, Ana M. Zubiaga, and Begoña Ochoa. A role for transcription factor e2f2 in hepatocyte proliferation and timely liver regeneration. American Journal of Physiology-Gastrointestinal and Liver Physiology, 301(1):G20–G31, July 2011. URL: http://dx.doi.org/10.1152/ajpgi.00481.2010, doi:10.1152/ajpgi.00481.2010. This article has 35 citations.](https://doi.org/10.1152/ajpgi.00481.2010)

[10. (Iglesias2004Diabetes) Ainhoa Iglesias, Matilde Murga, Usua Laresgoiti, Anouchka Skoudy, Irantzu Bernales, Asier Fullaondo, Bernardino Moreno, José Lloreta, Seth J. Field, Francisco X. Real, and Ana M. Zubiaga. Diabetes and exocrine pancreatic insufficiency in e2f1/e2f2 double-mutant mice. Journal of Clinical Investigation, 113(10):1398–1407, May 2004. URL: http://dx.doi.org/10.1172/jci18879, doi:10.1172/jci18879. This article has 2 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci18879)